Kusajili – Clinical trials directory

Result of your search per sponsor: Lexicon Pharmaceuticals Incorporated

Woman and Man Max 99 years
Lexicon Pharmaceuticals Incorporated Update Il y a 4 ans

A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI) with a Lead-in, Open-Label, Single-Dose Relative Bioavailability Study of LX6171 Oral Suspension in Healthy Elderly Subjects In stage A, the primary objective is: - To compare the relative bioavailability of a single dose of 300 mg LX6171 using a 40mg/mL and an 80mg/mL formulated suspension; - To evaluate plasma concentrati...

Country None
organs None
Specialty None

Closed trial

More information